Skip to content
Home
Close Home
Open Home
Journal information
Editorial board
Operations manual
Editorial policies
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Close Read
Open Read
Archive
TOC Alert
Current issue
Information
Close Information
Open Information
Editorial & Peer Review
Ethical policies
Funding
Complaints and appeals
Open access and licensing
Authors
Sponsorship
Contact
Publish
Close Publish
Open Publish
Instructions to authors
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
ES
EN
0,00
€
0
Cart
TOC Alert
Review Articles
Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat
NS5A Resistance: Clinical Implications and Treatment Possibilities
Mouse Models for Studies of In Vivo Functions of HIV-1 Nef
Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir
HIV and HCV Therapies in 2016: Optimal Regimens
News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference
Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs
HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review
Central nervous system disorders in HIV-infected individuals using distinct antiretroviral drugs
The spectrum of infectious pathogens in patients with primary or secondary immunodeficiency